During the first weekend in May, a very important event took place in Tinseltown. It wasn’t a movie premiere or a celebrity plugging their latest product. In fact, it was much more exciting! The annual American Society of Cataract and Refractive Surgery (ASCRS) meeting took place in Los Angeles. While there, our very own Dr. Rajesh Rajpal hosted an event on Corneal Collagen Cross-Linking.
An expert panel of doctors was assembled to discuss the science, implementation, and future of Collagen Cross-Linking. Collagen Cross-Linking is used to treat eyes with progressive keratoconus, a condition in which the normally round cornea thins and bulges outward into a cone shape. Cross-Linking can also be used in individuals who experience ectasia after refractive surgery. Ectasia occurs when the inner layers of the cornea become weak, causing the cornea to change shape, protrude forward, and distort vision.
As the Chief Medical Officer of Avedro, which has produced the only FDA approved Corneal Collagen Cross-Linking device in the United States, Dr. Rajpal hosted and moderated the Cross-Linking event co-sponsored by Avedro and the Cornea Society. It was noted during this event that since its approval approximately one year ago, there are 1,500 Cross-Linking systems in the U.S. and over 250,000 treatments have been performed. See Clearly Vision is proud to be one of the first and primary practices to conduct the clinical trials for approval of Corneal Collagen Cross-Linking. To learn more about Collagen Cross-Linking, please call 703-827-5454 to schedule an appointment today.
